EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 32 / No 8-9 (Août–Septembre 2016) Med Sci (Paris), 32 8-9 (2016) 716-718 References
Issue
Med Sci (Paris)
Volume 32, Number 8-9, Août–Septembre 2016
Nos jeunes pousses ont du talent !
Page(s) 716 - 718
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20163208018
Published online 12 September 2016
  1. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010 ; 55 : 560–578. [CrossRef] [PubMed] [Google Scholar]
  2. Ferré P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 2010 ; Suppl 2 : 83–92. [CrossRef] [PubMed] [Google Scholar]
  3. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARγ. Annu Rev Biochem 2008 ; 77 : 289–312. [CrossRef] [PubMed] [Google Scholar]
  4. Maceyka M, Harikumar KB, Milstien S, et al. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 2012 ; 221 : 50–60. [CrossRef] [Google Scholar]
  5. Qi Y, Chen J, Lay A, Don A, et al. Loss of sphingosine kinase 1 predisposes to the onset of diabetes via promoting pancreatic a-cell death in diet-induced obese mice. FASEB J 2013 ; 27 : 4294–4204. [CrossRef] [PubMed] [Google Scholar]
  6. Osawa Y, Seki E, Kodama Y, et al. Acid sphingomyelinase regulates glucose and lipid metabolism in hepatocytes through AKT activation and AMP-activated protein kinase suppression. FASEB J 2011 ; 25 : 1345–1353. [CrossRef] [PubMed] [Google Scholar]
  7. Kowalski GM, Kloehn J, Burch ML, et al. Overexpression of sphingosine kinase 1 in liver reduces triglyceride content in mice fed a low but not high-fat diet. Biochim Biophys Acta 2015 ; 1851 : 210–219. [CrossRef] [PubMed] [Google Scholar]
  8. Chen J, Wang W, Qi Y, et al. Deletion of sphingosine kinase 1 ameliorates hepatic steatosis in diet-induced obese mice: Role of PPARg. Biochim Biophys Acta 2016 ; 861 : 138–147. [CrossRef] [Google Scholar]
  9. Bellini L, Campana M, Mahfouz R, et al. Targeting sphingolipid metabolism in the treatment of obesity/type 2 diabetes. Expert Opin Ther Targets 2015 ; 19 : 1037–1050. [CrossRef] [PubMed] [Google Scholar]
  10. Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol 2011 ; 11 : 403–415. [CrossRef] [PubMed] [Google Scholar]
  11. Cuvillier O. Les récepteurs de la sphingosine 1-phosphate. De la biologie à la physiopathologie. Med Sci (Paris) 2012 ; 28 : 951–957. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  12. Moran-Salvador E, Lopez-Parra M, Garcia-Alonso V, et al. Role for PPARg in obesity-induced hepatic steatosis as determined by hepatocyte and macrophage-specific conditional knockouts. FASEB J 2011 ; 25 : 2538–2550. [CrossRef] [PubMed] [Google Scholar]
  13. Geng T, Sutter A, Harland MD, et al. SphK1 mediates hepatic inflammation in a mouse model of NASH induced by high saturated fat feeding and initiates proinflammatory signaling in hepatocytes. J Lipid Res 2015 ; 56 : 2359–2371. [CrossRef] [PubMed] [Google Scholar]
  14. Fayyaz S, Henkel J, Japtok L, et al. Involvement of sphingosine 1-phosphate in palmitate-induced insulin resistance of hepatocytes via the S1P2 receptor subtype. Diabetologia 2014 ; 57 : 373–382. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.